Cancer Research and Treatment

Paulo Rodrigues

1 Article

Adjuvant Effect of IV Clodronate on the Delay of Bone Metastasis in High-Risk Prostate Cancer Patients: A Prospective Study: Paulo Rodrigues, Flavio O. Hering, Alex Meller; Cancer Res Treat. 2011;43(4):231-235. Published online December 27, 2011; DOI: https://doi.org/10.4143/crt.2011.43.4.231

PURPOSE
High-risk prostate cancer patients undergoing treatment often experience biochemical recurrence. The use of bisphosphonates as an adjuvant treatment delays skeletal events, yet whether or not bisphosphonates also delay metastastic development remains to be determined.
MATERIALS AND METHODS
A total of 140 high-risk prostate cancer patients who were undergoing definitive treatment and who had clinically organ-confined disease and who suffered from biochemical recurrence were administered intravenous (IV) clodronate. The patients were treated with a radical retropubic prostatectomy (RP) or curative radiotherapy (RTx). Upon androgen deprivation therapy initiation, tri-monthly IV clodronate was added to the treatment to prevent bone demineralization. Twenty-six out of 60 operated cases and 45 out of 80 irradiated cases received bisphosphonate. The length of time until the first bone metastasis was recorded and analyzed.
RESULTS
No statistical difference was found for the type of primary treatment (RP or RTx) on the time to the first bone metastasis (95% confidence interval [CI], 0.40 to 2.43; p=0.98). However, there was a clear advantage favoring the group that received bisphosphonate (p<0.001). The addition of bisphosphonate delayed the appearance of the first bone metastasis by seven-fold (95% CI, 3.1 to 15.4; p<0.001).
CONCLUSION
Treatment with tri-monthly IV clodronate delayed the time to the first bone metastasis in high-risk prostate cancer patients who were experiencing an increase in the prostate specific antigen level after definitive treatment.

Citations

Citations to this article as recorded by

Interactions between cancer cells and bone microenvironment promote bone metastasis in prostate cancer
Xiangyu Zhang
Cancer Communications.2019;[Epub] CrossRef
Bone-Targeted Therapies in Cancer-Induced Bone Disease
Sofia Sousa, Philippe Clézardin
Calcified Tissue International.2018; 102(2): 227. CrossRef
Role of Hormonal Treatment in Prostate Cancer Patients with Nonmetastatic Disease Recurrence After Local Curative Treatment: A Systematic Review
Roderick C.N. van den Bergh, Niels J. van Casteren, Thomas van den Broeck, Eve R. Fordyce, William K.M. Gietzmann, Fiona Stewart, Steven MacLennan, Saeed Dabestani, Joaquim Bellmunt, Michel Bolla, Erik Briers, Philip Cornford, Steven Joniau, Malcolm D. Ma
European Urology.2016; 69(5): 802. CrossRef
Cancer Stem Cells and Macrophages: Implications in Tumor Biology and Therapeutic Strategies
Bruno Sainz, Emily Carron, Mireia Vallespinós, Heather L. Machado
Mediators of Inflammation.2016; 2016: 1. CrossRef
Osteopontin is a useful predictor of bone metastasis and survival in patients with locally advanced nasopharyngeal carcinoma
Xue Hou, Xuan Wu, Peiyu Huang, Jianhua Zhan, Ting Zhou, Yuxiang Ma, Tao Qin, Rongzhen Luo, Yanfen Feng, Ying Xu, Likun Chen, Li Zhang
International Journal of Cancer.2015; 137(7): 1672. CrossRef
Recent advances in bone-targeted therapies of metastatic prostate cancer
Xiyun Deng, Guangchun He, Junwen Liu, Feijun Luo, Xiaoning Peng, Shigang Tang, Zhiyong Gao, Qinlu Lin, Jill M. Keller, Tao Yang, Evan T. Keller
Cancer Treatment Reviews.2014; 40(6): 730. CrossRef
Clodronate inhibits tumor angiogenesis in mouse models of ovarian cancer
Nicole M Reusser, Heather J Dalton, Sunila Pradeep, Vianey Gonzalez-Villasana, Nicholas B Jennings, Hernan G Vasquez, Yunfei Wen, Rajesh Rupaimoole, Archana S Nagaraja, Kshipra Gharpure, Takahito Miyake, Jie Huang, Wei Hu, Gabriel Lopez-Berestein, Anil K
Cancer Biology & Therapy.2014; 15(8): 1061. CrossRef
Ibandronate increases the expression of the pro-apoptotic gene FAS by epigenetic mechanisms in tumor cells
R. Thaler, S. Spitzer, H. Karlic, C. Berger, K. Klaushofer, F. Varga
Biochemical Pharmacology.2013; 85(2): 173. CrossRef
A new bisphosphonate derivative, CP, induces gastric cancer cell apoptosis via activation of the ERK1/2 signaling pathway
Hai-jun Wang, Yu Liu, Li-qiao Fan, Cai-li Han, Ye Jiang, Shu-jie Cheng, Yong Li
Acta Pharmacologica Sinica.2013; 34(12): 1535. CrossRef

9,811 View
51 Download
9 Crossref

Author index